Introduction
The overall decline in cancer death rates is largely attributable to our increased understanding of disease pathogenesis, thus affording new opportunities for the prevention, early detection and moleculartargeted treatment of some of the most highly prevalent cancer types. In contrast, the molecular architecture of head and neck squamous cell carcinoma (HNSCC), a tumor type that has been responsible for $12 000 deaths in the USA during 2004 alone (1), still remains not fully understood (2, 3) . Although various therapeutic options are now becoming available to treat this disease, the 5-year survival rate for these tumors has improved only marginally for the last 30 years (1). The poor prognosis associated with this disease is largely due to both local invasion and the regional and/or distant metastatic spread of tumor cells. Indeed, patients with signs of metastatic disease have very poor prognosis (17% 5-year survival rate) (4, 5) . Arguably, a better understanding of the molecular mechanisms underlying the invasive and metastatic properties of HNSCC cells is required to help improving patient treatment and survival.
The acquisition of a motile and invasive phenotype is a crucial event in the progression of localized malignancies to a widespread metastatic disease [reviewed in ref . 6] . Recent findings have provided evidence that this step involves both intrinsic pathways activated in cancer cells as well as extrinsic cues emanating from the surrounding microenvironment (6) (7) (8) . These intrinsic and extrinsic signaling pathways in turn often converge to stimulate the activity of members of the Rho family of Ras-related GTP-binding proteins, including RhoA, Rac and Cdc42, which control the organization of the actin cytoskeleton thereby regulating cell adhesion, polarity and motility (9) (10) (11) . It is now known that these biological activities are coordinated by the concerted action of different Rho/Rac subfamily members. For instance, RhoA function is required for the initial formation of the lamellipodia and the establishment of focal adhesions and stress fibers, Rac1 promotes membrane ruffles and lamellipodia and Cdc42 trigger filopodia in the leading edge of migrating cells (10, 11) .
Based on this previous evidence, we decided to test the activation status of some of these GTPases in a large collection of HNSCC cell lines derived from well-defined clinical stage tumors (T2-T4) and displaying known genetic and molecular alterations that are typical of HNSCC (12) (13) (14) (15) (16) (17) in order to begin dissecting the molecular events responsible for the migration and invasiveness of this tumor type. This experimental strategy revealed that most HNSCC cells exhibit remarkably high levels of GTP-bound Rac1. Instead, the levels of activation of Ras, RhoA and Cdc42 varied more widely in the same cell types. Further analysis revealed that the activation of Rac1 in these HNSCC cells could be due to two independent signaling events, an epidermal growth factor receptor (EGFR)-initiated pathway that leads to the activation of the Rac1 exchange factor Vav2 and an EGFR/Vav2-independent pathway utilized by oncogenic mutants of the H-ras proto-oncogene. Finally, we provide evidence indicating that the EGFR/Vav2/Rac1 axis is a crucial pathway for the acquisition of motile and invasive properties of most HNSCC cells. These findings shed light onto the molecular mechanisms by which HNSCC cells acquire the ability to invade their surrounding tissues, and suggest that inhibiting Rac1 or its downstream targets may provide novel therapeutic opportunities to prevent HNSCC tumor dissemination and metastasis.
Materials and methods

Cell lines and culture conditions
Culture conditions of the HNSCC cell panel used in this study have been described in detail elsewhere (14, 15) . Briefly, cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum at 37°C in 95% air/5% CO 2 . HaCaT (spontaneously immortalized and non-tumorigenic human skin epidermal keratinocytes) and HEK293T (human embryonic kidney) epithelial cells were cultured as described above.
Cell stimulation
Epidermal growth factor (EGF) purchased from Sigma-Aldrich, St Louis (MO) was prepared as 100 lg/ml stock solution in 10 mM acetic acid containing 0.1% bovine serum albumin (BSA), according to manufacturer's instruction, and used at 100 ng/ml for 10 min unless indicated. N-(3-chlorophenyl)-6,7-dimethoxy-4-quinazolinamine (AG1478; EMD Biosciences, La Jolla, CA), an inhibitor of the EGFR was prepared as stock solution in dimethyl sulfoxide and diluted in media for the required concentration (10-50 lM).
Assessment of GTP levels of Ras superfamily proteins
Relative activity of the small GTPases (Ras, Rac1 and RhoA) was assessed by virtue of the ability to affinity precipitate their active GTP-bound forms upon their binding to effector domains that have been fused to glutathione-Stransferase bound to glutathione-Sepharose 4B beads, essentially as reported previously (18, 19) . Briefly, HNSCC and HaCaT cells were grown to 70-80% confluency, serum starved for 24 h and left untreated or followed by the indicated treatment (EGF stimulation, AG4178 inhibition and inhibition prior to stimulation) and cells were subsequently lysed with ice-cold buffer containing 10 mM Tris, 100 mM NaCl, 1% Triton X-100, 0.5 mM ethylenediaminetetraacetic acid, 40 mM b-glycerophosphate, 10 mM MgCl 2 , 1 mM Na 3 VO 4 , 10 lg/ml aprotinin, 10 lg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride. Cellular debris was removed by centrifugation followed by protein determination of the supernatants by a colorimetric assay method (Bio-Rad, Hercules, CA). Equivalent (0.8-1.0 mg protein) amounts of total cellular lysates were then incubated at 4°C for precisely 30 min with 20-40 lg of purified, bacterially expressed (pGEX) glutathione-S-transferase fusion protein, containing the GTP-RhoA-binding domain of rhotekin-RhoA-binding domain, the Rac1-Cdc42-binding domain of p21/Cdc42/Rac1-activated kinase 1 (PAK1) or the RAS-binding domain of c-RAF1, previously immobilized to glutathione-Sepharose 4B beads (GE Healthcare, Piscataway, NJ). Next, after three washes in lysis buffer, the beads were boiled in 1Â protein loading buffer, and the released proteins were resolved on 12% polyacrylamide-sodium dodecyl sulfate gels, transferred onto Immobilon-P membrane (Millipore Corporation, Bedford, MA), and the active form of the GTPases were detected using the indicated primary antibodies (Rac1, 1:1000, R56220, BD Biosciences, San Jose, CA; RhoA, 1:500, sc-26C4, Santa Cruz Biotechnology, Santa Cruz, CA; Pan-Ras, 1:1000, Ab-4, Calbiochem) and horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse secondary antibodies (Santa Cruz), followed by enhanced chemiluminescence (Pierce, RockFord, IL) and autoradiography. In parallel, 50 lg of total cellular lysates were similarly resolved and subsequently assessed for total levels of Rac1, RhoA and Ras proteins. The same lysates were further utilized to monitor EGFR levels and activity, using antibodies recognizing total and phosphorylated forms of the protein (1:1000; 610017 and E12120, respectively; BD Biosciences).
Lysates recovered from pull-down experiments were further used to immunoprecipitate (1 h at 4°C) total tyrosine-phosphorylated proteins using a mixture of antibodies recognizing the phosphotyrosines (PY99, Santa Cruz; 4G10, Upstate Millipore, Charlottesville, VA; PY20, ICN Pharmaceuticals: Costa Mesa, CA; PY100, Cell Signaling, Beverly MA), and the captured complexes (GammaBind; GE Healthcare), after washing, were resolved and detected for the indicated protein with the appropriate antibodies.
Pre-designed siRNA oligonucleotides were utilized to target Vav2 and H-Ras for knock-down experiments. Two Vav2 sequences (#1: 5#-GGAACAGCGAGCUGUUUGAtt-3#; #2: 5#-GGGAUCAGGCCUUUUCCCUtt-3#) and a single H-Ras sequence (5#-GCAGAUCAAACGGGUGAAGtt-3#) together with control siRNA (all from Ambion, Austin, TX) were used to transfect (20 nM) into exponentially growing HNSCC cells using HiPerFect Transfection reagent (Qiagen, Valencia, CA). Cells were incubated for 48 h prior to serum starvation (12 h), and harvested for the presence of the active form of Rac1. Where indicated, H-Ras and ERK2 (C-20 and C-14, respectively; Santa Cruz) and b-tubulin (556321, BD Biosciences) were used to monitor protein loading. Anti-Vav2 rabbit polyclonal antibodies were generated by us using a synthetic peptide corresponding to the Vav2 acidic region.
Cell migration assays Serum-free DMEM containing 0.1% BSA was placed in the bottom wells of a Boyden chamber whereas similar medium containing 5 Â 10 4 HNSCC cells was added to the top chamber. The two chambers were separated by a poretics polycarbonate polyvinylpyrrolidone free 8 l pore size membrane (Osmonics, GE Osmonics Labstore, Minnetonka, MN) pre-coated with 50 lg/ml collagen IV (Trevigen, Gaithersburg, MD). After incubation for 9-12 h, the chamber was disassembled ensuring minimal disruption of migrated cells, and the membrane stained with Diff-Quick Stain (Dade Behring Inc., Deerfiled, IL), placed on a glass slide and the positively stained cells were quantified microscopically by counting 20 random high-power fields per filter. EGF (10-100 ng/ml) in serum-free DMEM containing 0.1% BSA was placed in the bottom wells and served as a positive chemoattractant for cell migration. One-way analysis of the variance of the migration data was performed followed by the Tukey's test to examine the differences among cell lines and test groups. A value of P , 0.05 was considered to be statistically significant. cells seeded on top of the dried Matrigel in the inserts. DMEM/BSA containing EGF (100 ng/ml), or DMEM/BSA alone as control, was added to the lower chamber, and plates were incubated at 37°C for 24 h. Filters were fixed (4% formaldehyde/phosphate-buffered saline), stained with crystal violet (0.2% crystal violet in 2% ethanol) and after removing the contents of the upper membrane surface, invasive cells were microscopically counted in 20 random high-power fields per filter. For Vav2 knock down, exponentially growing cells were transfected, using HiPerFect Transfection reagent (Qiagen), with 20 nM of either control or Vav2 (#1) siRNA and after that incubated for 48 h. Cells were then serum starved and processed for invasion assay as detailed above. Statistical analysis of the data was performed as described above for migration assays.
Matrigel invasion assays
Construction of expression libraries from HNSCC cells
Total RNA was extracted from exponentially growing HNSCC cells using Trizol (Invitrogen, Carlsbad, CA) and followed by the purification of mRNA following provided instructions (mRNA Purification Kit, GE Healthcare). Next, the mRNA was used as template to construct cDNA expression libraries in the pEAK8 cloning vector essentially following the provided guidelines (Edge BioSystems, Gaithersburg, MD),
Selection of transforming clones and focus formation assays
To identify transforming sequences from HNSCC cells, bacteria transformed with the primary cDNA expression library ($2 Â 10 6 individual clones) were plated in 20 independent pools (10 5 bacterial clones each), and DNA plasmids and bacterial stocks generated from each pool. Pools containing transforming sequences were identified by transfecting NIH 3T3 cells and counting cell foci after 2 weeks of culture, as described previously (20) . Only two pools contained focus-forming sequences, and each was divided into 20 subsequent pools ($5000 colonies per plate). Secondary pools containing the highest numbers of transforming plasmids were sequentially divided into 20 pools for two more rounds, until individual transforming plasmids were identified and sequenced.
Amplification, subcloning and sequencing of exon 1 of the H-ras locus Genomic DNA isolated from HNSCC cells was used as template to amplify exon 1 of the human proto-oncogene c-H-Ras using the standard polymerase chain reaction method and the following primers: 5#-AGACCCTGTAGGAG-GACCCC; 3#-CTGGGCTCGCCCGCAGCAGCTGCTGG. Next, the expected 206 bp polymerase chain reaction products were excised from the gel, purified and subcloned into the pGEM-T Easy Vector System (Promega, Madison, WI) for subsequent sequence analysis using T7 (forward) and SP6 (reverse) primers.
Expression plasmids
Wild-type human H-Ras and the corresponding V12 mutant were subcloned into the pCEFL-KZ AU5 expression vector (19) . For the D12 mutant, the DNA was initially amplified from the pEAK8 expression library and the 570 bp, and inserted into the pCEFL-KZ AU5 vector. All clones were sequence verified prior to further biochemical analysis. Next, the ability of c-H-Ras and related mutants to influence GTPase activiy was assessed in vitro. Briefly, 293T cells were transfected with the indicated plasmids, and incubated for a further 12-16 h prior to serum starvation for an additional 12-16 h cells. Cells were lysed at 4°C and processed to detect GTP-Rac1 activity essentially as described above. AU5 (Covance, Denver, PA) tag antibody was used to monitor the expression efficiency of the transfected plasmids. Expression plasmids for Vav2 were used as positive controls (19) .
Generation of adenoviral particles and viral infection of eukaryotic cells
Production of high-titer recombinant adenovirus using the AdEasy system has been described previously (21) . Adenoviruses encoding the myc-epitopetagged dominant-negative Rac1 cDNA containing a substitution at position 17 (Rac1
N17
; provided by Dr Toren Finkel, National Institutes of Health) was essentially prepared and amplified as described (22) . Briefly, the high-titer viral stock was initially used to transfect 911 cells, and subsequently amplified using fresh 911 cells. The control virus expressed green fluorescent protein (GFP) (Adeno-GFP). Amplified virus underwent purification by cesium chloride centrifugation and subsequent titration was performed by plaque assay in lowpassage 293 cells using the Adeno-X Rapid Titer kit and instructions provided in the manual (Invitrogen). A series of preliminary infections were performed in a subset of the cell lines each to determine the optimal dose of virus based on its limited cytotoxicity and effects on the growth rate when compared with the mock-infected cells. All subsequent infections were performed at a multiplicity of infection of 50 for 12 h on cells that had been maintained in culture for 24 h (serum free). Assessment of gene transfer efficiency after infection was by western blot as well as by examination of high-efficiency GFP expression.
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Results
Detection of activation levels of endogenous GTPases in epithelial cells
As Rho/Rac GTPases are only active during a short window of time upon cell stimulation, we initially wished to set up experimental conditions that could be compatible with the reproducible detection of the activated levels of endogenous Ras superfamily proteins in tumor cells. For this purpose, we first evaluated whether variations in the GTP levels of a number of GTPases could be detected in HaCaT, an immortalized, non-tumorigenic epithelial cell line (23) . To this end, we performed pull-down experiments with appropriate glutathione-S-transferase fusion protein probes to detect GTP-loaded GTPases in quiescent and stimulated cells (see Materials and Methods). As shown in Figure 1 , these conditions allowed the detection of the rapid and transient stimulation of Ras, Rac1 and RhoA upon stimulation of quiescent cells with either EGF or serum ( Figure 1 and data not shown, respectively), indicating that they were probably optimal for the detection of active GTPases in tumor cells.
Activation of Rac1 is a common feature in HNSCC cell lines
We next used these pull-down experiments to monitor the activation status of Rac1, RhoA and Ras in a representative panel of nine HNSCC cell lines (HN8, HN12, HN13, HN17, HN19, HN22, HN26, HN30 and HN31). These cell lines were selected based on their known pattern of genetic aberrations and typical alterations of signaling pathways (12) (13) (14) (15) (16) (17) 24) . As a control, we used the EGF-stimulated HaCaT cells to demonstrate the detection of GTP-loaded GTPases under these conditions. In addition, we used immunoblot analysis of total cellular lysates using antibodies to Ras proteins and b-tubulin to demonstrate the equal loading of all samples. These experiments indicated that Ras was activated in more than half of the selected HNSCC cell lines ( 9) . In parallel experiments, we also observed that most HNSCC cells exhibit a similar level of active Cdc42 (data not shown). In contrast with the above results, we found that Rac1 is activated in a wide range of HNSCC cells (Figure 2, third panel from top, lanes 2-4 and 6-9 ). These levels of activity were similar, or even higher, than those induced by EGF in HaCaT cells (Figure 2 , third panel from top, lane 11). Immunoblot analysis confirmed that all GTPases were expressed at similar levels with the only exception of the loss of RhoA in the HN13 cell line (Figure 2 , second, fourth and sixth panels from top). This was not due to unequal loading, since b-tubulin and the rest of GTPases were detected in that sample (Figure 2, bottom panel) . These data indicate that constitutive activity of Rac1 is a common and specific feature of most HNSCC cells.
A role for Rac1 in HNSCC migration and invasion We initially assessed HNSCC cell lines displaying contrasting levels of GTP-Rac1 for cell migration using Boyden chamber assays. Consistent with the role of Rac1 in cell migration, cells with elevated levels of GTP-Rac1 (HN12, HN13, HN17 and HN26) displayed a high basal migratory activity, whereas those cells with low (HN8 and HN19) to medium (HN22) Rac1 activity, migrated less efficiently ( Figure 3A) . The migratory activity of most HNSCC cells was further enhanced upon treatment of cells with chemoattractants such as serum or EGF. The only exception was HN30 cells that had elevated basal migratory activity but impaired chemotaxis toward EGF ( Figure 3A) . To examine whether this motility was Rac1 dependent, we evaluated whether the inactivation of the endogenous Rac1 protein could lead to the reduction of the migratory activity of HNSCC cells. To this end, we expressed in the indicated cell lines the dominant-negative version of Rac1 (Rac1 N17 mutant) using an adenoviral gene delivery system (22) . This strategy allowed the expression of Rac1 N17 at significantly higher levels than the endogenous wild-type Rac1 protein both in HaCaT and HNSCC cells (Figure 3B , insert; data not shown). Under these conditions, Rac1 N17 caused a significant reduction in both the basal and EGF-stimulated migratory activity of HaCaT, HN12 and HN13 cells, as an example. In contrast, it was totally ineffective when over-expressed in HN30 cells.
We next investigated whether Rac1 N17 could influence the capacity of these HNSCC cells to invade in vitro using Matrigel layers in the presence or absence of EGF. As shown in Figure 3B , mock-transfected HNSCC, but not HaCaT cells, invaded the matrix in basal culturing conditions. As expected, similar to HaCaT cells, most HNSCC exhibiting limited Rac1 activity displayed poor basal invasive potential (data not shown). EGF enhanced such behavior in all tumoral and non-tumoral cells with the single exception of the HN30 cell line ( Figure 3C ). Likewise, the over-expression of Rac1 N17 abrogated Fig. 1 . EGF activates Ras and Rho GTPases in HaCaT cells. HaCaT cells were serum starved followed by EGF stimulation (100 ng/ml) for the indicated times. Cells were lysed and equivalent amounts of the recovered protein were subsequently incubated with the appropriate Sepharose-bound glutathione-S-transferase fusion proteins including the Ras-, Rac1-and RhoA-binding region of Raf-1 (RAF), PAK1 (PAK) and rhotekin, respectively. GTP-bound forms of these GTPases were washed and resolved together with total extracts, by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by western blot analysis using antibodies recognizing Ras (top panel), Rac1 (middle) and RhoA (bottom). Data shown are representative of those obtained from three independent experiments. AP, affinity precipitation; TCL, total cell lysate. 
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the invasiveness of all cell lines but that of HN30 ( Figure 3B ). Taken together, these findings suggest that Rac1 does play an essential role in the chemoattractant-induced migration and invasion of most HNSCC cells. However, there is a small population of HNSCC cell lines, reflected by HN30, whose migration/invasiveness is Rac1 independent.
Persistent tyrosine phosphorylation of Vav2 in HNSCC cells
We next sought to investigate the mechanism underlying the elevated activity of Rac1 in HNSCC cells. In this regard, considering that a large fraction of the HNSCC cells display elevated activity of the EGFRs (24), we focused our attention on the Vav family of Rho/Rac guanine nucleotide exchange factors, as they act downstream from both receptor and non-receptor tyrosine kinases (25) . Among the Vav family members, Vav1 and Vav3 are primarily expressed in cells of the immune system, whereas Vav2 is widely expressed, including in cells of epithelial origin (25) . Thus, Vav2 represented the best candidate to mediate the activation of Rac1 in HNSCC cells. The catalytic activity of this GEF family is regulated by direct phosphorylation on tyrosine residues, a property that allows monitoring its level of activation in vivo by performing anti-phosphotyrosine immunoprecipitations Fig. 3 . A role for Rac1 in HNSCC cell migration and invasion. Serum-starved HNSCC cells were assessed either in the presence or absence of EGF for their ability to migrate using a Boyden chamber. Serum-free DMEM containing 0.1% BSA (control) or EGF (100 ng/ml) (EGF) was placed in the lower part of the chamber, whereas cells in DMEM/0.1% BSA were added to the top part of the Boyden chamber, with both components separated by a membrane. After incubation (9-12 h), the chamber was dismantled and cell migration was assessed by counting the stained cells attached to the membrane. Data are represented as the number of cells in 20 random high-power fields ± SEM in triplicate membranes from a representative experiment (A). Next, HaCaT cells infected with Adeno-GFP and Adeno-Rac1 N17 were assessed by western blot for efficiency of gene delivery (B, insert). Uninfected cells (5 Â 10 4 ) (control) or cells infected with Adeno-GFP or Adeno-Rac1 N17 were assessed for their migratory activity toward wells containing medium without (C) or with EGF (EGF), as described above. Data are represented as the number of cells in 20 random high-power fields ± SEM in triplicate membranes from a representative experiment (B). For invasion, similar control and treated cells in DMEM/0.1% BSA were placed into Transwell inserts coated with Matrigel. Either DMEM/BSA containing EGF (100 ng/ml) (EGF) or DMEM/BSA alone as control (C) was added to the lower chamber and incubated at 37°C for 24 h, after which the cells were fixed and stained, and invasive cells were microscopically counted in 20 random high-power fields per filter. Data are represented as the number of invading cells ± SEM from a typical experiment run in triplicate (B). Analysis of the variance and Tukey's post-test statistical analysis was performed to compare among cell lines and groups, as indicated (ÃP , 0.05, ÃÃP , 0.01 and ÃÃÃP , 0.001).
V. Patel et al. or immunoblots (19, 25, 26) . To assess the activation levels of Vav2, cell lysates from HNSCC cells were immunoprecipitated with antiphosphotyrosine antibodies and the presence of this GEF was determined by anti-Vav2 immunoblots. As shown in Figure 4 (top panel), high levels of phospho-Vav2 were observed in six out of the nine cell lines tested. Two of the cell lines negative for Vav2 phosphorylation expressed reduced or non-detectable levels of Vav2 protein (Figure 4 , compare the first and second panels). Anti-ERK2 immunoblots confirmed that all samples contained similar amounts of loaded material (Figure 4, bottom  panel) . As observed previously in other cell types, non-tumoral cells showed low levels of phospho-Vav2 unless they were stimulated with mitogens such as EGF (Figure 4, top panel on the right) . In the case of control HaCaT cells, this phosphorylation was mediated by the EGFR as judged by the dramatic drop of Vav2 phosphorylation in cells that had been treated with AG1478, an specific EGFR inhibitor (Figure 4 , top panel on the right). These data indicate that the constitutive tyrosine phosphorylation of the Rac1 GEF Vav2 is a common feature in most HNSCC cells, suggesting that the Vav2/Rac1 axis is a common point of signal convergence in these cells.
Of interest, one HNSCC cell line, HN8, exhibited a persistently elevated level of tyrosine-phosphorylated Vav2 (Figure 4 ), but not enhanced Rac1 activity (see above, Figure 2) , thus raising the possibility that Vav2 phosphorylation may not be sufficient to activate Rac1. Alternatively, considering that certain Rho and Rac GAPs, such as p190 RhoGAP, can be stimulated by tyrosine phosphorylation (27) , it is still conceivable that in this cell line EGF may trigger two opposing and thus counteracting effects on Rac1, by regulating its GEFs and GAPs simultaneously. On the other hand, a possibility still exists that the overall tyrosine phosphorylation of Vav2 may not reflect fully its activation state, as in HN8 cells, Vav2 may not be phosphorylated in certain specific tyrosine residues that are required to elevate its Rac-GEF activity (25) . These and additional possibilities that may help explain why this particular cell line exhibiting detectable levels of tyrosine-phosphorylated Vav2 does not display increased Rac1 activity are under current investigation.
Rac1 activation in HNSCC occurs through EGFR/Vav2-dependent and -independent routes
Given that Vav2 is a target of the EGFR and that this tyrosine kinase receptor is frequently activated in HNSCC cells, we next investigated whether the constitutive high levels of activated Rac1 in those cells were dependent on an EGFR-initiated signaling event. This hypothesis was evaluated by measuring the levels of phosphorylated EGFR by immunoblot analysis. We selected for these studies the HN13 and HN30 cell lines because they show high levels of Rac1 activity but different patterns of Vav2 phosphorylation (see above). These experiments indicated that quiescent, non-stimulated HN13 cells have detectable levels of EGFR activity ( Figure 5A, top panel, lane 1) . This activity was significantly enhanced upon stimulation of cells for 5 min by EGF ( Figure 5A, top panel, lane 3) . The phosphorylation levels of the EGFR in both conditions could be eliminated upon treatment of cells with the AG1478 inhibitor ( Figure 5A , top panel, lanes 2 and 4, respectively), indicating that this assay was a bonafide reporter of the kinase activity of this membrane receptor. The same cell lysates were then used to estimate the stimulation status of Rac1 and its upstream regulator Vav2. The activation of both Rac1 and Vav2 followed an identical profile to that observed before for the EGFR ( Figure 5A , third and fifth panels from top), suggesting that this receptor does promote the stimulation of the Vav2/Rac1 signaling pathway. Immunoblot analysis confirmed the presence of equal amounts of each of these proteins in the lysates under study ( Figure 5A , second, fourth, sixth and seventh panels from top). Interestingly, HN30 cells showed a different behavior under identical experimental conditions, since no variations in the levels of either Rac1 or Vav2 were observed upon EGF stimulation or AG1478 treatment ( Figure 5B , third and fifth panels from top). This was not due to alterations in the signaling of the EGFR, since this molecule underwent similar responses to EGF and AG1478 when compared with the HN13 cell line ( Figure 5B , top panel). These results indicate that activation of Rac1 in HNSCC cells can occur through two different signaling mechanisms.
To characterize the former route that promotes Rac1 activation in HNSCC cells, we used two siRNAs to knock down the human vav2 mRNA. As shown in Figure 6A (third panel from top, lanes 3-6), these siRNAs (referred to as #1 and #2) effectively reduced the levels of the endogenous Vav2 protein. This effect was specific, since a control siRNA did not have any effect on the expression levels of this GEF ( Figure 6A, third panel from top, lanes 1 and 2) . The levels of other unrelated proteins were not affected either ( Figure 6A , second and fourth panels from top). Interestingly, the reduction in the levels of Vav2 protein led to the abrogation of the EGF-dependent activation of Rac1 in those cells ( Figure 6A , top panel, compare lanes 4 and 6 with lane 2), further indicating that Vav2 acts as the crucial signaling molecule that links EGFR stimulation with the activation of Rac1 in HN13 cells. Similar results were observed in HaCaT cells (data not shown). However, in good agreement with our previous data (see Figure 5 ), the elimination of Vav2 protein did not have any effect in the constitutive high levels of Rac1 in HN30 cells ( Figure 6B , top panel). Likewise, the depletion of Vav2 protein decreased the basal and EGF-dependent invasive activity of HN12 and HN13 cells ( Figure 6 ) and in HaCaT cells when used as controls (data not shown). In contrast, it had no negative influence on the invasion behavior of HN30 cell line (Figure 7 ). Taken together, these results indicate that there are two alterative pathways to promote Rac1 activation in HSNCC cells: one of them relies on the activation of the EGFR/ Vav2 signaling route whereas the other one is independent on these two molecules.
The Ras pathway mediates Rac1 activation in HN30 cells
To identify the nature of the second pathway that mediates Rac1 activation in certain HSNCC cells, we decided to look for the presence of oncogenic events in HN30 cells. We hypothesized that if the constitutive activity of Rac1 in HN30 cells were due to the presence of an oncogenic mutation, that oncogene could be identified by focus formation assays using expression cDNA libraries derived from HN30 transcripts. To this end, we first cloned HN30-derived cDNAs in an EF-1-driven mammalian expression vector and the resulting cDNA library was then used to transfect NIH 3T3 cells and the presence of potential oncogenic transcripts visualized by the generation of foci of transformed cells (see Materials and Methods). This expression cloning strategy led to the identification of multiple plasmids encoding a missense mutation (G 12 / D) in the H-ras proto-oncogene ( Figure  8A ). This mutation was further corroborated by the detection of this Fig. 4 . Phosphorylation of Vav2 in HNSCC. Total cell lyates from exponentially growing HNSCC cells were used to immunoprecipiate tyrosine-phosphorylated proteins with a cocktail of appropriate antibodies (PY20, PY99, PY100 and 4G10). The protein complexes were captured (GammaBind), washed and subsequently analyzed by western blot for the presence of phosphorylated Vav2. Total expression levels of Vav2 were monitored in parallel using 50 lg of the same total cell lysates. Loading control was assessed by ERK2 expression. As additional controls, lysates from HaCaT cells, either untreated or pre-treated with AG1478 followed by stimulation with EGF, were analyzed by western blot for the status of phosphorylation of Vav2, together with that of total Vav2 and ERK. The data shown are representative of those obtained from three independent experiments.
Aberrant signaling through Rac1 in oral cancer mutation in the exon 1 of H-ras locus of HN30 cells. The wild-type allele was also detected in these assays, indicating that these cells were heterozygous for the mutation (data not shown). This mutation was also found in the HN31 cell line but not in the rest of cells used in our study. This is probably to the fact that the HN30 and HN31 cell lines were both isolated from the same cancer patient (14) . However, HN31 cells exhibited lower levels of activated H-Ras, which may explain their reduced Rac1 activity as compared with HN30 (see above, Figure 2A , top and middle panels).
To test that the H-Ras G12D mutant was sufficient to induce the activation of Rac1 in vivo, we performed pull-down experiments to detect the activation levels of Rac1 in the presence or absence of this Ras mutant. As comparative controls, we also included in these experiments the wild-type version of H-Ras, the standard oncogenic version of H-Ras (G12V mutant) and the oncogenic version of Vav2. As shown in Figure 8B (upper panel), mock-transfected and H-Rasexpressing cells do not have detectable levels of GTP-bound Rac1. In contrast, the expression of either H-Ras G12V or H-Ras G12D was sufficient to induce levels of activation of Rac1 comparable with those found in Vav2 oncoprotein-expressing cells. These data supported that the EGFR/Vav2-independent pathway involved in the activation of Rac1 in HN30 cells is likely initiated downstream of the H-Ras oncoprotein.
To validate the contribution of H-Ras G12D in the activation Rac1 in HN30 cells, we utilized siRNA technology targeting H-Ras in these cells to examine if this would result in a decreased level of active Rac1. HN13 cells were also assessed as a control. As seen in Figure  8C HN30 (B) HNSCC cells were either untreated, pre-treated with AG1478, stimulated with EGF, or pre-treated with AG1478 followed by EGF, as indicated, and total cell lysates (TCLs) were analyzed by western blot for activated and total levels of EGFR proteins. In parallel, lysates were immunoprecipitated (IP) with anti-phosphotyrosine antibodies or affinity precipitated (AP) with glutathione-S-transferase-PAK, and analyzed for the presence of Vav2 or Rac1, respectively. Total levels of Vav2 and Rac1 were also determined in cell lysates. Immunoblotting for b-tubulin served as a loading control. All experiments were performed in triplicates. cells transfected with the appropriate siRNA. Total Rac1 and b-tubulin levels were also monitored as loading controls. These findings supported the role of mutated H-ras in promoting the constitutive elevated levels of active Rac1 in HN30 cells.
Discussion
Previous publications have shown that GTPases of the Rho family are frequently over-expressed in different cancer types, an event that usually correlates with a poor outcome (28, 29) (reviewed in ref. 30) . However, most studies have been based primarily on the analysis of mRNA expression that may not necessarily reflect actual changes in protein expression and/or function. In this context, the detection of GTP-bound Rho/Rac proteins is likely to be more informative from a functional point of view. Based on this body of information, we have analyzed the activation status of a number of Ras and Rho/Rac GTPases in HNSCC cells. Our results revealed that HNSCC cells display remarkably high levels of GTP-bound Rac1, a molecular event that correlates with the enhanced migration and invasion of these cells. In contrast, the activation of Ras and RhoA shows a much more restricted profile, and we did not observe major differences in the levels of active Cdc42 among the different HNSCC cell lines. While searching for the underlying mechanism that promotes the activation of this GTPase, we found that HNSCC cells can promote Rac1 activation at least by two independent and mutually exclusive routes. The most prevalent pathway is based on the over-activity of EGFR, and the downstream activity of the Rac1 GEF Vav2.
Several lines of evidence support that Rac1 is activated downstream from EGFR through Vav2 in most HNSCC cells. Indeed, decreasing the activity of EGFR with EGFR inhibitors reduced the basal and EGF-stimulated accumulation of Rac1-GTP. In addition, activation of Rac1 correlated well with the recovery of Vav2 in anti-phosphotyrosine immunoprecipitates, and Vav2 phosphorylation was sensitive to EGFR blockade. Furthermore, reducing Vav2 expression levels by RNA interference techniques decreased both the basal levels of active Rac1 as well as the activation of this GTPase by EGF. Taken these data together, we can postulate that the over-activity of an EGFR/ Vav2/Rac1 signaling route is a frequent event in HNSCC. In addition, the observations that the basal and EGF-stimulated invasiveness of HNSCC that have elevated activity of this pathway is totally blocked using vav2-specific siRNA and the Rac1 N17 dominant-negative mutant further support the emerging concept that that the EGFR/Vav2/ Rac1 route is essential for the enhanced migratory and invasive activity of most HNSCC cells.
A less prevalent pathway that participates in the activation of Rac1 in HNSCC cells is the constitutive activation of the Ras route due to a missense mutation in the H-ras locus. The discovery of H-ras mutations in a small subset of HNSCC cell lines is somewhat unexpected. Indeed, previous studies have shown that these mutations are quite rare in the Western population, although they are detected at rather high levels (35%) in a betel quid-chewing patient cohort from Southeast Asian countries (3, (31) (32) (33) . In addition to the effects that the expression of the mutant H-Ras G12D protein may have in the wellknown Ras downstream elements, this protein promotes the effective activation of Rac1 independently of extracellular stimuli. The mechanism by which H-Ras G12D promotes Rac1 activation is hitherto unknown. Tiam1, a Rac1-specific GEF that is regulated by direct binding to Ras proteins (34) , is expressed in HNSCC cells. However, in contrast to previous results, we could not detect any specific interaction between Tiam1 and H-Ras G12D in our cells. It is also plausible to hypothesize that H-Ras G12D may mediate activation of Rac1 via a different downstream target such as phosphatidylinositol 3-kinase or other Rac-GEFs. Further work in this area may help identify the specific signaling pathway linking H-Ras G12D with Rac1 in these cells.
Of interest, the effects of H-Ras G12D on Rac1 are probably independent of the specific ras mutation because its best-described mutant, H-Ras G12V (35) , induces similar levels of Rac1 activation, at least upon its ectopic expression ( Figure 8B ). HN30 also exhibited very high levels of active RhoA, thus raising the possibility that in HNSCC cells harboring ras mutations their protein products may stimulate the activity of a yet to be identified GEF acting on both RhoA and Rac1 GTPases. On the other hand, inhibition of Rac1 by the use of its dominant-negative mutant did not decrease the basal migratory and invasive capacity of HN30 cells. These cells are characterized for the presence of a wild-type p53 (15), and nonetheless are quite resistant to pro-apoptotic stimuli such as c-radiation and DNAdamaging agents (36) . Thus, we cannot rule out that in cells harboring ras mutations, Rac1 may not contribute to their migratory activity, but instead Rac1 may play additional roles, including the regulation of cell proliferation and survival (37) , which warrants further investigation. In summary, our data indicate that most HNSCC cells exhibit a persistently active EGFR/Vav2/Rac1 signaling axis that contributes to tumor invasion and metastasis. In this regard, Rac1 can coordinate the activation of molecules involved in the remodeling of the actin cytoskeleton, such as the serine-threonine kinase PAK1, with the stimulation of intracellular kinase cascades regulating c-jun N-terminal kinase, a member of the mitogen-activated protein kinase superfamily (B) To test the ability of this mutation to activate Rac1, AU5-tagged H-Ras (WT, V12 and D12) were transfected in HEK293T cells and after serum starvation, cell lysates were assessed for the presence of active form of Rac1, using the expression of Vav2 as a positive control. Expression of AU5-tagged Ras proteins was confirmed, and total levels of Rac1 and total Ras proteins (pan-Ras) were used as loading controls. (C) Knock down of H-Ras decreases Rac1 activation in HN30 but not in HN13 cells. Levels of activated Rac1 were assessed in cells untransfected (C) and transfected with control or H-Ras siRNA after affinity precipitation (AP) of GTP-Rac1 with glutathione-S-transferase-PAK, as described above. Total cell lysates (TCLs) from these samples were further analyzed by western blotting to detect the total levels of Rac1 and H-Ras, using b-tubulin as a loading control. Notice the reduction in H-Ras expression levels in cells transfected with its targeting siRNA.
Aberrant signaling through Rac1 in oral cancer of serine-threonine kinases, which in turn may regulate the expression of proteases involved in the active remodeling of the extracellular matrix and tissue invasion (9) (10) (11) 38, 39) . Thus, in this scenario, our present findings suggest that inhibiting Rac1 GEFs, Rac1 itself or specific Rac1 downstream targets, such as PAK1 and c-jun N-terminal kinase, may represent an effective strategy to prevent HNSCC tumor dissemination and metastasis, especially in patients exhibiting EGFR hyperactivity.
